PDX153 was the only PDX with an oncogenic PIK3CA mutation (p.K111E) reported to confer sensitivity to the treatment [14], and indeed, we observed a significant reduction of 83% in the tumor volume after 35 days of treatment (i.e., a PR outcome). This evidence concerns the gene PIK3CA and neoplasm.